|
|
|
|
MBC Alumni, Proteologix, Acquired by Johnson & Johnson for $850M
In case you missed it, Proteologix Inc., has been acquired by Johnson & Johnson for $850M. Proteologix began their journey at MBC BioLabs San Carlos in 2021 with four lab benches and quickly made progress developing bispecific antibodies for immunology and inflammation with a small and dedicated team of scientists. The company’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus TSLP, ready to advance to Phase 1 for moderate to severe atopic dermatitus and asthma. Behind PX128 is PX130, a bispecific antibody targeting IL-13 plus IL-22, in preclinical development for moderate to severe atopic dermatitis. These treatments aim to offer high efficacy by targeting multiple disease pathways, addressing major unmet medical needs in atopic dermatitis and asthma treatment.
The acquisition by Johnson & Johnson is to our knowledge, the largest ever for a preclinical stage company, and will enhance Johnson & Johnson’s dermatology portfolio with a potential best-in-disease treatment for atopic dermatitis and asthma.
Enabling Awesome
At MBC BioLabs, we believe that startups are the greatest for positive change in the world. We are dedicated to “enabling awesome” by fostering innovation and helping biotech companies achieve their goals. We would like to congratulate the Proteologix team on this monumental achievement and can't wait to see what they accomplish next.
► PRESS RELEASE
|
|
Mission BioCapital Platinum Program 2024
Mission BioCapital has opened the call for applications to the 2024 Platinum Ticket Program. Apply for $500k in funding, access to lab space and core equipment at any MBC BioLabs facility, mentorship and support from Ono Ventures, Eli Lilly, and Mission BioCapital, and drug discovery services from Alloy Therapeutics.
► APPLY UNTIL JULY 15
|
|
|
|
NEWS FROM OUR RESIDENT AND ALUMNI COMPANIES
|
|
|
Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies
► READ MORE
|
|
|
Celldom Lands $938K Phase II SBIR Grant From NCI
► READ MORE
|
|
|
Multiply Labs Inks $85M Deal with Retro Bio to Automate Cell Therapy Manufacturing
► READ MORE
|
|
|
Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing
► READ MORE
|
|
|
Gilead Pays $20M to Join Cartography's Next-gen Cancer Medicine Expedition
► READ MORE
|
|
|
Flow Cytometry Panel Building Seminar and Workshop with Miltenyi
June 24 @ 10 - 11am
930 Brittan Ave, San Carlos
Come for breakfast and join our partners at Miltenyi for flow cytometry training and a free customized panel design based on your markers of interest.
► REGISTER
|
|
|
Agilent Lunch & Learn
June 25 @ noon - 1pm
135 Mississippi St, San Francisco
Meet Agilent's TapeStation specialists and learn informative tips and tricks to get the best results from their instruments available in our cores.
► REGISTER
|
|
|
Partner Office Hours
Connect with our partners from Cytiva, Malvern Panalytical, Agilent, Eppendorf, Revvity, or MilliporeSigma during their scheduled office hours this month!
► CHECK THE CALENDAR
|
|
|
|
UPCOMING FOUNDERS AT WORK SPEAKER SERIES
|
|
|
AcureX Biosciences
July 2 @ noon - 1pm
930 Brittan Ave, San Carlos
Topic: Harnessing Precision Medicine to Develop Novel Therapeutic Approaches for Neurodegenerative Diseases
► REGISTER
|
|
|
Mammoth Biosciences
July 25 @ noon - 1pm
135 Mississippi St, San Francisco
Topic: Delivering on the Promise of Genetic Medicine with Next-Generation CRISPR Cures
► REGISTER
|
|
|
Merge Therapeutics
Merge Therapeutics is developing dual-action antibodies targeting independent, clinically-validated drivers of autoimmune disease. Our lead program broadly inhibits both T and B cell activity, for transformative efficacy in diseases such as rheumatoid arthritis, lupus, and type 1 diabetes. Co-founders Lauren and Brad have worked together over 5 years, most recently at a clinical-phase immunology company, and have extensive experience discovering, developing, and commercializing therapeutic antibodies.
We warmly welcome Co-founder and CEO Lauren Gehman, and CSO Brad Youngblood to the 930 Brittan Community in San Carlos!
|
|
|
Siren Biotechnology
Siren Biotechnology is developing the world's first AAV gene therapy platform for cancer. Their Universal AAV Immuno-Gene Therapy combines the promise of two transformative therapeutic technologies, AAV gene therapy and cytokine immunotherapy, into a single modality that is poised to redefine how tumor cells are destroyed and anti-tumor immunity is elicited.
We are excited to welcome Founder and CEO Nicole Paulk, Director of Preclinical Research Lauren Kelly, Chief of Staff Akela Kawahara, and Associate Scientist Chris Lovejoy to our 953 Indiana community in San Francisco.
|
|
|
|
SPECIAL THANKS TO OUR PARTNERS
|
|
|
|
|
|
|
|
MBC BioLabs - Enabling Awesome
|
|
|
|
|
|
|
